American Society of Hematology

$Patients with high-risk treatment-naive or relapsed/refractory CLL/small lymphocytic lymphoma were randomized to 200 mg daily (QD) or 100 mg twice daily (BID) of acalabrutinib. (A) Trough BTK occupancy was serially measured (at day 4 and 1, 6, and 12 months) in PBMCs, showing higher occupancy in the twice-daily dosing cohort at all time points and increased BTK occupancy over time. (B) BTK occupancy in PBMC, bone marrow, and lymph nodes was measured during a 36- to 48-hour dose hold, allowing calculation of BTK resynthesis rates and demonstrating close correlation between BTK occupancy in PBMCs and in tissue compartments. *P ≤ .05; **P ≤ .01; ****P ≤ .0001. The figure has been adapted from Figures 4 and 5 in the article by Sun et al that begins on page 93. Professional illustration by Brian Cannon.$

Patients with high-risk treatment-naive or relapsed/refractory CLL/small lymphocytic lymphoma were randomized to 200 mg daily (QD) or 100 mg twice daily (BID) of acalabrutinib. (A) Trough BTK occupancy was serially measured (at day 4 and 1, 6, and 12 months) in PBMCs, showing higher occupancy in the twice-daily dosing cohort at all time points and increased BTK occupancy over time. (B) BTK occupancy in PBMC, bone marrow, and lymph nodes was measured during a 36- to 48-hour dose hold, allowing calculation of BTK resynthesis rates and demonstrating close correlation between BTK occupancy in PBMCs and in tissue compartments. *P ≤ .05; **P ≤ .01; ****P ≤ .0001. The figure has been adapted from Figures 4 and 5 in the article by Sun et al that begins on page 93. Professional illustration by Brian Cannon.

This Feature Is Available To Subscribers Only